Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab in severe or critical COVID-19
NCT04347239Phase 2Completed
- Sponsor
- CytoDyn Inc.
- Start
- Apr 2020
- Primary completion
- Oct 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of leronlimab in coronavirus disease 2019 (COVID-19), sponsored by CytoDyn Inc.. Started Apr 2020; status: completed.
02
Drugs
leronlimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04347239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347239.